Journal Article

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Experience From the US Lymphoma CAR T Consortium

Clinical Advances in Hematology and Oncology (2022) 20(2) 16-17
DOI: 10.1200/jco.2022.40.16_suppl.e19583
0Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.
Get full text

Cite

CITATION STYLE

APA

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Experience From the US Lymphoma CAR T Consortium. (2022). Clinical Advances in Hematology and Oncology, 20(2), 16–17. https://doi.org/10.1200/jco.2022.40.16_suppl.e19583

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free